Drugs / PRILIXIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004816 | Jul 1995 → ? | multiple sclerosis | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRILIXIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108475 ↗ |
| Known as | CEN 000029 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108475 ↗ |
| Known as | CM-MT412 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108475 ↗ |
| Known as | CMT-412 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108475 ↗ |
| Known as | M-T412 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004816 ↗ |
| Modality | Monoclonal antibody | “a chimeric murine-human anti-CD4 monoclonal antibody” NCT00004816 ↗ |
| Route | Intravenous | “receiving a single dose intravenously over 2 hours” NCT00004816 ↗ |
| Target | CD4 | “a chimeric murine-human anti-CD4 monoclonal antibody” NCT00004816 ↗ |